Drug Delivery and Nanotechnology Module

项目概要-纳米技术 药物输送和纳米技术（DD&N）模块是一个可用的技术资源 威尔默眼科研究所的教员，通过持续和有针对性的药物输送， 玻璃体内、结膜下或全身给药，以及开发新的成像技术。 技术.在目前这段时间里，这些合作带来了许多NIH的赠款， 出版物，许多专利授权，和重大的翻译工作，与多种治疗 由威尔默P30团队开发的方法正在进行临床转化。DD&N需要 利用威尔默眼科研究中心的专业知识、技术和资源， 纳米医学（CNM）。威尔默的纳米医学中心是DD&N的锚 模块，并已发展到七个教师，与超过15个教师在威尔默和更多的合作 约翰霍普金斯的100多名教员。威尔默研究人员的需求（包括已成立的和早期的 研究人员）用于开发和表征小分子的药物递送系统， 蛋白质和核酸的增长远远超出了全国妇女委员会现有的预算限制， 随着DD&N成为P30努力的一个组成部分。我们的共同努力， 用于治疗青光眼，视神经损伤， 早产儿视网膜病和干眼。DD&N模块将继续蓬勃发展， P30合作者的重大发现。

PROJECT SUMMARY – NANOTECHNOLOGY The Drug Delivery and Nanotechnology (DD&N) module is an enabling technology resource available to faculty of the Wilmer Eye Institute, by enabling sustained and targeted delivery of drugs administered intravitreally, subconjunctivally, or systemically, and in developing novel imaging technologies. During the current period, the collaborations have resulted many NIH grants, publications, many patents licensed, and significant translational efforts, with multiple therapeutic approaches developed by the Wilmer P30 team undergoing clinical translation. DD&N takes advantage of the expertise, technologies, and resources of the Wilmer Eye Institute’s Center for Nanomedicine (CNM). The Center for Nanomedicine at Wilmer serves as an anchor for the DD&N module, and has grown to seven faculty, collaborating with more than 15 faculty in Wilmer and more than 100 faculty across Johns Hopkins. Demand by Wilmer investigators (both established and early investigators) for the development and characterization of drug delivery systems for small molecules, proteins, and nucleic acids have grown well beyond the available budgetary restrictions of the CNM, with the DD&N becoming an integral part of the P30 effort. Our collaborative efforts have led to significant progress in novel therapeutic approaches for the treatment of glaucoma, optic nerve injury, retinopathy of prematurity, and dry eye. The DD&N module will continue to thrive and enable significant discoveries by the P30 collaborators.